Skip to main content

Table 3 Number of subjects categorized according to time spent in remission divided by subject-specific follow-up duration, for each of the remission criteria tested

From: Sustained rheumatoid arthritis remission is uncommon in clinical practice

All subjects in BRASS with ≥2 years of follow-up
Time in remission (%) DAS28-CRP < 2.6
N= 871a
DAS28-CRP < 2.3
N= 871a
SDAI
N= 871a
CDAI
N= 871a
ACR/EULAR
N= 871a
0 326 (37%) 401 (46%) 599 (69%) 610 (70%) 634 (73%)
1-25 130 (15%) 146 (17%) 94 (11%) 30 (3%) 87 (10%)
26-50 196 (23%) 163 (19%) 108 (12%) 127 (15%) 101 (12%)
51-75 121 (14%) 102 (12%) 52 (6%) 66 (8%) 39 (4%)
76-99 52 (6%) 30 (3%) 10 (1%) 17 (2%) 7 (1%)
100 46 (5%) 29 (3%) 8 (1%) 21 (2%) 3 (0.3%)
Overall mean time in remission 31% 24% 12% 15% 10%
Selected population of subjects in BRASS
Time in remission (%) DAS28-CRP < 2.6
N = 309 b
DAS28-CRP < 2.3
N = 275 b
SDAI
N = 168 b
CDAI
N = 170 b
ACR/EULAR
N = 158 b
1-25 77 (25%) 89 (32%) 58 (35%) 54 (32%) 60 (38%)
26-50 133 (43%) 111 (40%) 62 (37%) 72 (42%) 64 (41%)
51-75 49 (16%) 37 (13%) 30 (18%) 24 (14%) 18 (11%)
76-99 28 (9%) 21 (8%) 6 (4%) 7 (4%) 8 (5%)
100 22 (7%) 17 (6%) 12 (7%) 13 (8%) 8 (5%)
Overall mean
time in remission
48% 45% 44% 44% 42%
  1. aSubjects in BRASS with ≥2 years of follow-up. Maximum number of visits is eight. bSubjects in BRASS with ≥2 years of follow-up, one or more visits in remission, according to the various
  2. definitions; ≥1 year follow-up after first visit in remission and not in remission at entrance into
  3. BRASS. Maximum number of visits is seven (because visit at entrance into BRASS is excluded).